Potent antitumor efficacy of an E1B 55kDa‐deficient adenovirus carrying murine endostatin in hepatocellular carcinoma

No abstract is available for this paper.

• Publication year

  2005

• Venue

  International Journal of Cancer

• Publication date

  2005-02-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ijc.20581PMID 15389517
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus

  2002cited by this paper
• Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma

  2002cited by this paper
• Cytolytic viruses as potential anti-cancer agents.

  2002cited by this paper
• Replication-selective viruses for cancer therapy

  2002cited by this paper
• Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus

  2002cited by this paper
• Gene-viral vectors: a promising way to target tumor cells and express anticancer genes simultaneously.

  2002cited by this paper
• Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer.

  2001cited by this paper
• E1B-Deleted Adenovirus (dl1520) Gene Therapy for Patients with Primary and Secondary Liver Tumors

  2001cited by this paper
• Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics

  2001cited by this paper
• 2000 Report of the AVMA Panel on Euthanasia.

  2001cited by this paper
• Report of the AVMA panel on euthanasia

  2001cited by this paper
• Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays.

  2001cited by this paper
• Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

  2000cited by this paper
• Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases.

  2000cited by this paper
• Restricted replication-competent adenovirus: a novel strategy for cancer gene therapy

  2000cited by this paper
• Replication-selective adenoviruses as oncolytic agents.

  2000cited by this paper
• Oncolytic potential of E1B 55 kDa‐deleted YKL‐1 recombinant adenovirus: Correlation with p53 functional status

  2000cited by this paper
• Gene therapy: trials and tribulations

  2000cited by this paper
• Squalene: potential chemopreventive agent

  2000cited by this paper
• Oncolytic viruses as novel anticancer agents: turning one scourge against another

  2000cited by this paper
• Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015)

  2000cited by this paper
• Replicative adenoviruses for cancer therapy

  2000cited by this paper
• Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.

  2000cited by this paper
• Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene

  1999cited by this paper
• Targeting the Replication of Adenoviral Gene Therapy Vectors to Lung Cancer Cells: The Importance of the Adenoviral E1b-55kD Gene

  1999cited by this paper
• Antiangiogenic gene therapy

  1999cited by this paper
• Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies.

  1999cited by this paper
• The Replicative Capacities of Large E1B-Null Group A and Group C Adenoviruses Are Independent of Host Cell p53 Status

  1999cited by this paper
• p53-Independent and -Dependent Requirements for E1B-55K in Adenovirus Type 5 Replication

  1999cited by this paper
• p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma.

  1999cited by this paper
• Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice.

  1999cited by this paper
• p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection

  1998cited by this paper
• Replication of ONYX-015, a Potential Anticancer Adenovirus, Is Independent of p53 Status in Tumor Cells

  1998cited by this paper
• trans E1 component requirements for maximal replication of E1-defective recombinant adenovirus.

  1998cited by this paper
• Antiangiogenic gene therapy.

  1998cited by this paper
• The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53.

  1998cited by this paper
• A Novel Three-Pronged Approach to Kill Cancer Cells Selectively: Concomitant Viral, Double Suicide Gene, and Radiotherapy

  1998cited by this paper
• ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

  1997cited by this paper
• Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

  1997cited by this paper
• Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

  1997cited by this paper
• Replicating viruses as selective cancer therapeutics.

  1996cited by this paper
• An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells

  1996cited by this paper
• Implications of the p53 tumor-suppressor gene in clinical oncology.

  1995cited by this paper
• Therapy of unresectable hepatocellular carcinoma.

  1995cited by this paper
• Treatment of hepatocellular carcinoma: too many options?

  1994cited by this paper
• Postresection prognosis of patients with hepatocellular carcinoma.

  1993cited by this paper
• Report of the AVMA panel on euthanasia.

  1978cited by this paper

• Oncolytic Adenovirus in Cancer Immunotherapy

  2020cites this paper
• Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy

  2020cites this paper
• Oncolytic Adenoviruses in Gastrointestinal Cancers

  2018cites this paper
• Oncolytic virotherapy in upper gastrointestinal tract cancers

  2018cites this paper
• Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma

  2018cites this paper
• Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

  2015cites this paper
• Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses.

  2013cites this paper
• Update on oncolytic viral therapy – targeting angiogenesis

  2013cites this paper
• Combining virotherapy and angiotherapy for the treatment of breast cancer

  2013cites this paper
• Experimental studies on treatment of pancreatic cancer with double-regulated duplicative adenovirus AdTPHre-hEndo carrying human endostatin gene.

  2013cites this paper
• Oncolytic adenoviruses in anticancer therapy: Current status and prospects

  2012cites this paper
• Impact of tumor microenvironment on oncolytic viral therapy.

  2010cites this paper
• Increasing the Efficacy of Oncolytic Adenovirus Vectors

  2010cites this paper
• ANTIANGIOGENIC GENE THERAPY ON HEPATOCELLULAR CARCINOMA USING ENDOSTATIN AND SONOPORATION IN VIVO

  2010cites this paper
• Analysis of the Transport Behavior of Escherichia Coli in a Novel Three-Dimensional In Vitro Tumor Model

  2010cites this paper
• Oncolytic (replication-competent) adenoviruses as anticancer agents

  2010cites this paper
• Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes.

  2009cites this paper
• An update on gene therapy in China.

  2009cites this paper
• "Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment.

  2009cites this paper
• Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy

  2008cites this paper
• Adenoviral Gene Therapy for Pancreatic Cancer: Where Do We Stand?

  2008cites this paper
• Drug resistance in hepatoblastoma.

  2007cites this paper
• Gene Therapy and the Evolution of Cancer Treatment

  2007cites this paper
• p53 gene in treatment of hepatic carcinoma: status quo.

  2007cites this paper
• Angiogenesis Research to Improve Therapies for Vascular Leak Syndromes, Intra-abdominal Adhesions, and Arterial Injuries

  2007cites this paper
• Gene transfer of endostatin enhances the efficacy of doxorubicin to suppress human hepatocellular carcinomas in mice

  2007cites this paper
• Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

  2006cites this paper
• Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.

  2006cites this paper
• Markedly Enhanced Cytolysis by E1B-19kD-Deleted Oncolytic Adenovirus in Combination with Cisplatin

  2006cites this paper
• Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinoma.

  2006cites this paper
• Current World Literature

  2006cites this paper
• Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action.

  2006cites this paper
• Emerging drugs for hepatocellular carcinoma

  2006cites this paper
• Studies on viral gene transfer and angiogenesis inhibition in experimental glioma models

  2006cites this paper
• Preparation of gene-viral therapeutic system CNHK200-hA and its antitumor activity on lung cancer

  2006cites this paper
• Roles of p53 in Carcinogenesis, Diagnosis and Treatment of Hepatocellular Carcinoma

  2006cites this paper
• Adenovirus-based cancer gene therapy.

  2005cites this paper
• Hepatocellular carcinoma: molecular pathways and new therapeutic targets.

  2005influential citation
• Antiangiogenic strategies in hepatocellular carcinoma: current status

  2005cites this paper
• Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.

  2005cites this paper